High-Flying Biotech Valuations Are Falling – And Maybe That’s A Good Thing

Big Pharma Focused On Science, Not Prior Funding

Venture capitalists speaking at Biocom’s Global Life Science Partnering Conference looked forward to a return to rational valuations that could enable better returns for investors and pharma buyers.

Passenger airplane is flying in colorful sky at sunset — The sun is setting on high biotech valuations this year • Source: Alamy

Venture capital investors speaking at Biocom’s Global Life Science Partnering Conference did not exactly cheer declining biotechnology company valuations but they welcomed a return to more rational valuations that could justify further fundraising and deal-making at terms that make sense for investors and big pharma buyers.

“In the private investing area, I actually think this is a good thing that we're going to have some rationalization come into our valuations,” New Enterprise Associates (NEA) partner Carol

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Hengrui Set For Biggest Biopharma IPO So Far This Year

15 May 2025

• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

13 May 2025

• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

13 May 2025

• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.